Connect with us

Spread & Containment

Forced Vaccination Law In Denmark Abandoned After Public Protests

Forced Vaccination Law In Denmark Abandoned After Public Protests



Forced Vaccination Law In Denmark Abandoned After Public Protests Tyler Durden Wed, 11/18/2020 - 05:00

Authored by Paul Joseph Watson via Summit News,

A law in Denmark that would have given authorities the power to forcibly inject people with a coronavirus vaccine has been abandoned after nine days of public protests.

The ‘epidemic law’ would have handed the Danish government the power to enact mandatory quarantine measures against anyone infected with a dangerous disease, but it was the part about vaccinations that caused the biggest uproar.

“The Danish Health Authority would be able to define groups of people who must be vaccinated in order to contain and eliminate a dangerous disease,” reports the Local.

“People who refuse the above can – in some situations – be coerced through physical detainment, with police allowed to assist.”

However, after nine straight days of protests against the new law, it has now been scrapped.

With a coronavirus vaccine within sight, governments across the world are mulling over what punitive measures to bring against those who refuse to take it.

Last week we highlighted how both Ticketmaster and airline companies are considering barring people from entering venues and flying if they cannot prove they have taken the vaccine.

So while public protests may be able to prevent authorities carrying out forced vaccinations, people who refuse to take the shot may find it virtually impossible to enjoy any kind of social life, use public transport, or even find employment.

*  *  *

New limited edition merch now available! Click here.

In the age of mass Silicon Valley censorship It is crucial that we stay in touch. I need you to sign up for my free newsletter here. Also, I urgently need your financial support here.

Read More

Continue Reading

Spread & Containment

COVID-19 Vaccine Found In The Hearts Of Dead People: Study

COVID-19 Vaccine Found In The Hearts Of Dead People: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours)

COVID-19 vaccine…



COVID-19 Vaccine Found In The Hearts Of Dead People: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours)

COVID-19 vaccine was detected in patients who died within a month of vaccination, according to a new study.

COVID-19 vaccines in Massachusetts in a file image. (Joseph Prezioso/AFP via Getty Images)

U.S. researchers analyzed tissue samples from the autopsies of 25 people, including 20 who were vaccinated.

Samples from the hearts of three patients, all of whom died within 30 days of a Pfizer shot, tested positive for messenger ribonucleic acid (mRNA).

Eight bilateral axillary lymph node samples, from people who died within 30 days of a Moderna or Pfizer vaccine, also tested positive. The companies' shots utilize mRNA.

The research shows "the vaccine can persist for up to 30 days, including in the heart," Dr. James Stone, with the departments of pathology at Massachusetts General Hospital and Harvard Medical School, told The Epoch Times via email.

The study was published by npj Vaccines. Authors declared no conflicts of interest. They said the research was supported by Massachusetts General Hospital, which is in Boston.

In testing of heart and bilateral axillary lymph node tissues from other vaccinated people who died, no vaccine was detected.

Additionally, no vaccine was detected in the liver, spleen, or mediastinal lymph nodes—vaccine was detected in the liver and spleen in preclinical rodent studies before—nor was any detected in tissues from the unvaccinated patients.

The Pfizer and Moderna vaccines are known to cause myocarditis, a form of heart inflammation that can result in death.

The people who had mRNA detected in the heart did not have myocarditis, though they did have detectable heart injuries, researchers found.

The researchers said they believed the heart injuries stemmed from underlying diseases and not the vaccines.

"There is no indication as yet that the vaccine in the heart is causing any problems in these patients; neither the causes of death nor the causes of the myocardial injury were linked to the vaccines in that study," said Dr. Stone, one of the authors of the paper.

A health care worker prepares a dose Pfizer/BioNTEch COVID-19 vaccine at The Michener Institute, in Toronto, Canada, on Dec.14, 2020. (Carlos Osorio/POOL/AFP via Getty Images)

That position was challenged by Dr. Clare Craig, a British pathologist who reviewed the research.

"The vaccine should not have been there. There was evidence of heart damage. Those three people are now dead," Dr. Craig told The Epoch Times in a message.

She said the researchers were setting too high of a bar for causality.

"At postmortem if there is significant narrowing of the coronary arteries then heart damage is attributed to it on the balance of probabilities. Here this is a clear cut association, an unusual picture of myocardial injury, and a failure to call it out for what it is," Dr. Craig said.

More on Research

The tissues were collected from autopsies performed between January 2021 and February 2022 at the Massachusetts General Hospital. Researchers excluded tissues from some dead people, including from patients who had no clear history of vaccination or non-vaccination and those who had a documented prior COVID-19 infection.

The researchers wanted to test the tissue for vaccine in light of research that has found both spike protein and mRNA persisting in axillary lymph nodes and blood for weeks or even months after vaccination. The testing would help "gain a better understanding of the biodistribution and persistence of SARS-CoV-2 mRNA vaccines," they said. SARS-CoV-2 is the virus that causes COVID-19.

Researchers ended up with tissues from 20 vaccinated patients, including six who received one dose, 12 who received two doses, and two who received three doses. They also formed a control group of five unvaccinated patients.

Six bilateral axillary lymph node samples were available for people vaccinated with Moderna's shot. Two tested positive for the vaccine. Thirteen were available for people vaccinated with Pfizer's shot. Six tested positive for the vaccine.

Overall, of the 11 bilateral axillary lymph node samples from patients who died within 30 days of a shot, eight tested positive. None of the samples from patients who died beyond 30 days of vaccination tested positive.

Researchers also examined samples from each of the vaccinated people from the cardiac left ventricle and cardiac right ventricle. Of those, four samples tested positive across three patients. These were the three who received Pfizer's shot within 30 days of dying. The samples also tested negative for COVID-19.

Vaccine was not detected in any of the unvaccinated people.

The vaccinated patients were on average older, with a mean age of 64 compared to 57. A higher percentage—55 percent to 20 percent—had recent heart injury.

Read more here...

Tyler Durden Fri, 09/29/2023 - 18:20

Read More

Continue Reading


T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This…



Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.


T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay


The post T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact first appeared on Micro Cap Daily.

The post T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact appeared first on Micro Cap Daily.

Read More

Continue Reading

Spread & Containment

NPS team makes key breakthrough on path to electric aircraft propulsion

As an institution renowned for innovation efforts grounded in education and research, the Naval Postgraduate School (NPS) has often been called upon to…



As an institution renowned for innovation efforts grounded in education and research, the Naval Postgraduate School (NPS) has often been called upon to tackle some of the most difficult technological challenges facing the Navy and the nation.

Credit: Javier Chagoya, Naval Postgraduate School

As an institution renowned for innovation efforts grounded in education and research, the Naval Postgraduate School (NPS) has often been called upon to tackle some of the most difficult technological challenges facing the Navy and the nation.

Such a challenge emerged in 2020, when NASA charged NPS and two other research teams with solving a critical barrier facing the development of electric aircraft propulsion (EAP): the creation of a circuit breaker that could support large electric platforms running on direct current (DC) electricity. Thanks to the efforts of a diverse team of faculty and students, as well as several Navy and academic research partners, NPS delivered an innovative working prototype.

This past March, the successful test of the “Navy High Speed Solid-State Fault Management System for Electric Aircraft Propulsion” confirmed the breakthrough results. The NPS-led design was able to provide a viable DC circuit breaker to NASA, pushing the project development forward to Level 6 on the Technology Readiness Level scale – a 9-level measurement system used to assess the maturity of a particular technology.

The effort to research and design the DC circuit breaker for EAP was led by Dr. Di Zhang, NPS Associate Professor of Electrical and Computer Engineering, along with a team of NPS students. Zhang, who came to NPS in 2019 after working on electric power converter designs with General Electric’s Global Research Center, is widely considered one of the nation’s leading experts on large electric vehicles.

As a result of his team’s work, Zhang was awarded a $750,000 research grant by NASA to continue his research with a goal to refine the weight and performance of the team’s initial breaker design.

The breakthrough achieved at NPS could be a critical step in the development of EAP, one of many emerging technologies receiving increased attention due to the emphasis placed by the Secretary of the Navy, Carlos Del Toro, on accelerating innovation throughout the Department of the Navy.

“We are indeed in an innovation race — and it is one we must win,” said Del Toro during remarks at the Naval Research Laboratory in Washington, D.C., on Sept. 28. “Innovation must permeate every aspect of our Department’s approach to the delivery of the technologies and capabilities at a speed and scale necessary for our Navy and Marine Corps to confront the challenges of today and the future.”

NPS will play a significant role in supporting the development of EAP technology and other relevant innovation efforts following the establishment of the Naval Innovation Center (NIC) at NPS. First announced in December 2022, the NIC will leverage NPS education and research to drive “ideas to impact,” bringing research concepts out of the lab and into the field faster by empowering students, faculty and partners across the entire Naval Research & Development Establishment (NR&DE) to work with the naval innovation ecosystem and industry.

Accelerated innovation for technologies such as EAP is also facilitated through the Secretary of the Navy’s “Climate Action 2030” policy, which prioritizes the development of systems that are not dependent on fossil fuels, expanding the use of renewable energy and electric propulsion.

In addition to supporting Climate Action 2030 and similar policy goals, EAP can also enable numerous new design freedoms and functions, leading to lower energy consumption and higher propulsion efficiency. And, of course, the noise signature of combustion engines could be all but eliminated utilizing EAP, enhancing stealth capabilities of future systems.

“Electric propulsion technology is crucial for future Navy capabilities, offering enhanced design flexibility, supporting power-intensive advanced systems, and ensuring stealth, efficiency, and adaptability in evolving naval environments,” said Zhang. “The technology’s integration also paves the way for the adoption of emerging energy sources, solidifying the Navy’s technological edge.”

Zhang and his NPS student team were joined in their research efforts by partners from Virginia Tech, Clemson University and the University of Connecticut, and received engineering support from Naval Air Systems Command (NAVAIR) in China Lake, Calif., and the Naval Surface Warfare Center (NSWC) Philadelphia division.

According to Zhang, one of the fundamental questions when looking at utilizing electric power is the distinction between products that run on direct current and alternating current (AC).

“A hundred years ago, Nikola Tesla and Thomas Edison had a battle over the advantages of AC versus DC electric power. Tesla won, and now much of what we use and see is running on AC power,” said Zhang.

There are certain advantages to using AC electricity, he says. AC generators are the primary source of electric power, which are driven by steam, nuclear, or other power sources. AC can be transmitted across great distances and is also easily changed to different voltage levels through the use of transformers that can step voltage up and down. As its name implies, AC has an alternating current that runs in a sinusoidal pattern; this makes AC electricity relatively safe and easy to interrupt with a circuit breaker as the waveform naturally crosses zero.

Direct current has its own advantages that are rising in importance as technology looks to the future. DC systems require less cabling and can be smaller and lighter than AC systems, as well as more power efficient. Clean sources of energy – like wind and solar – store power in photovoltaic grids and batteries which are inherently DC compatible. Electric cars that use DC power are also able to use regenerative braking to return energy to their batteries, and they are run in a compact space that does not require long distance transmission.

“The trend we’re seeing in energy industries and in electric vehicles is this switch to DC, and that’s why it is so important to look towards this electric aircraft design,” explained Zhang. “With DC, we can make a design lighter and smaller with the same power which is critical for aviation and Navy applications. The target for this DC breaker design is to get the same amount of power while cutting the weight to one tenth of what’s been developed.”

One thing that doesn’t get smaller and lighter with DC systems is the circuit breaker. The challenge that NASA posed to NPS was to create a circuit breaker that could shut down an electric aircraft running at maximum power in a safe, simple – and size-efficient – way.

“Think of electricity flowing like water through a pipe. A circuit breaker is the tool you need to shut that water off. With DC, high amounts of current and voltage equate to a huge flow of water that is hard to shut down quickly,” explained U.S. Marine Corps Capt. Michael Smith, an NPS electrical engineering graduate. “That quick change from a high to low voltage, or high to low current, creates an electromagnetic field that can interfere with other electric systems.”

Capt. Smith is one of five NPS students who worked on the project with Zhang. Since his graduation in September 2022, he now applies his degree as an Expeditionary Energy Officer for the Marines. His master’s thesis focused on testing circuit boards to ensure they could withstand the electromagnetic interference of a large-scale DC circuit breaker, and he was able to successfully identify manufactured circuit boards that would function under the required conditions.

“The trick to reaching industry standards is in the balance,” said Zhang. “You need to design something new, but not too new or it is unproven and risky. You cannot only be innovative; you must also be practical. So, we had three years during a global pandemic, which hindered manufacturing and access to technology, to produce a result that is as safe and simple as possible.”

In spite of those challenges, the team was able to successfully meet the deadline. While Zhang is pleased with the achievement of his students and the positive feedback from NASA, he is far from done with this research.

“I’m very proud of the students that I’ve worked with who have shown great ability with hands-on research,” said Zhang. “I’m also proud of my team and colleagues here at NPS who have such strong industry experience and perspective towards electrical engineering. It’s with this perspective that we’re able to deliver something so practical, useful, and impactful.”

NPS Vice Provost for Research Dr. Kevin Smith complimented Zhang and his research team, noting the achievement as an exemplar of how basic and applied research at NPS leads to relevant technology solutions.

“Di Zhang’s accomplishment is a great example of how our faculty lead interdisciplinary research at NPS, leveraging our students’ operational insight and our innovation ecosystem of academic and industry partners to solve problems and drive concepts to capability,” said Dr. Smith.

Read More

Continue Reading